Chinese Chemical Letters p. 761 - 764 (2011)
Update date:2022-07-29
Topics:
Xue, Jian Jun
Yu, Xiao Ming
(-)-Clausenamide is a drug candidate under Phase I clinical trial for treatment of Alzheimer's disease (AD). In order to elucidate the substituent related structure-activity relationship, six one-substituent modified (-)-clausenamide analogues were designed, and four of them, namely 3-O-methyl, 6-O-methyl, 3-des-hydroxyl and 6-des-hydroxyl analogues were prepared by selective 3- and 6-OH modification of (-)-clausenamide.
View MoreShandong Xinke Petrochemical Co., Ltd.
Contact:+86-546-7277016
Address:Gudao Industrial Park, Hekou District, Dongying, Shandong Province, China
Shanghai Mokai Pharmaceutical Co.,Ltd
Contact:021-60257269
Address:Rm506,No.915,Zhenbei Road,Shanghai,200333,China
Contact:86-607-68073220
Address:1 ave na road jiahua st
Hangzhou Taiyan Trading Co., Ltd
Contact:+86-13777583958
Address:NO.63, Xingyi Street, Xihu District, Hangzhou, Zhejiang, China
Wuxi Innopal International Trade CO.,LTD
Contact:+86-510-80711901-8003
Address:Room 402,Building 5,Longze Garden,No.17,South huanjiu Road,Yixing City, Jiangsu,China
Doi:10.1039/b109198k
(2002)Doi:10.1002/pola.28166
(2016)Doi:10.1016/j.tetlet.2011.05.014
(2011)Doi:10.1021/jo01282a035
(1967)Doi:10.1021/ml200100t
(2011)Doi:10.1002/chem.201003251
(2011)